Jazz Pharmaceuticals
JAZZ
511 hedge funds and large institutions have $7.28B invested in Jazz Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 93 funds opening new positions, 169 increasing their positions, 172 reducing their positions, and 56 closing their positions.
131% more call options, than puts
Call options by funds: $17M | Put options by funds: $7.36M
66% more first-time investments, than exits
New positions opened: 93 | Existing positions closed: 56
33% more capital inflows, than outflows
Capital inflows: $709M | Capital outflows: $534M
11% more funds holding in top 10
Funds holding in top 10: 9 → 10 (+1)
7% more funds holding
Funds holding: 479 → 511 (+32)
4.29% more ownership
Funds ownership: 93.52% → 97.81% (+4.3%)
2% less repeat investments, than reductions
Existing positions increased: 169 | Existing positions reduced: 172
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$59.8M |
| 2 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$57.1M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$37.8M |
| 4 |
Sofinnova Investments
Menlo Park,
California
|
+$37.2M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$37.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$64.5M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$54.2M |
| 3 |
Polaris Capital Management
Boston,
Massachusetts
|
-$25.9M |
| 4 |
Woodline Partners
San Francisco,
California
|
-$23.8M |
| 5 |
Avidity Partners Management
Dallas,
Texas
|
-$23.2M |
JAZZ Hedge Fund Activity: Q4 2024 in Review
511 of the 7,623 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q4 2024, worth a combined $7.28B — up 13% from $6.43B a quarter earlier.
Buyers outnumbered sellers: 93 funds opened new JAZZ positions and 56 closed out — a net gain of 37 holders — while 169 added to existing stakes and 172 trimmed.
The largest buyer was Fuller & Thaler Asset Management, adding an estimated $59.8M. The largest seller was Citadel Advisors, cutting an estimated $64.5M.
- 511 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q4 2024, up from 479 in Q3 2024.
- Funds reported $7.28B of Jazz Pharmaceuticals stock for Q4 2024, up 13% quarter-over-quarter.
- 93 funds opened new Jazz Pharmaceuticals positions in Q4 2024 and 56 closed out, a net change of +37 holders.
- The largest Jazz Pharmaceuticals buyer in Q4 2024 was Fuller & Thaler Asset Management, an estimated $59.8M added.
- The largest Jazz Pharmaceuticals seller in Q4 2024 was Citadel Advisors, an estimated $64.5M sold.
Based on aggregated 13F filings for Q4 2024.